S1P Receptor Modulators for Remyelination in Demyelinating Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelination disorders, such as multiple sclerosis and other neurological conditions, are limited in effectiveness, with immunoregulatory drugs often postponing disability rather than preventing it, and there is a need for new treatments that can address demyelination caused by autoimmune dysfunction and other factors.
Innovation Solution
Development of compounds that act as S1P modulating agents and/or ATX modulating agents, specifically S1P4 antagonists or ATX inhibitors, which can modulate S1P receptor activity or ATX activity to treat conditions mediated by S1P or ATX activity, including inflammatory disorders, autoimmune disorders, and malignancies, thereby promoting oligodendrocyte progenitor cell differentiation and myelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunoregulatory drugs are used to treat demyelination disorders, then immune response is modulated, but disability progression is only postponed rather than prevented
Solution Approach 1:
The patent employs FTY720, a chemical compound that modifies the physiological parameters of lymphocyte trafficking by mimicking S1P (sphingosine-1-phosphate). This alters the natural behavior of immune cells, causing them to be retained in lymph nodes rather than migrating to the CNS, thereby providing a more effective treatment mechanism that addresses disability progression rather than merely postponing it.
2Adaptability or versatility
If S1P receptor activity is modulated to treat inflammatory and autoimmune disorders, then lymphocyte trafficking is altered, but specificity for particular receptor subtypes is challenging
Solution Approach 1:
The patent utilizes the natural tissue-specific expression pattern of S1P receptors to achieve selective therapeutic effects. Different S1P receptor subtypes (S1P1, S1P2, S1P3, S1P4, S1P5) are expressed in different tissues, and FTY720's ability to modulate these receptors produces localized effects in specific organs and systems, allowing for targeted treatment of inflammatory and autoimmune conditions while minimizing off-target effects.
Data Source
AI summary
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).